The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:
* Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC? * Can the genetic test results provide information about how a tumour will respond to or resist treatment?
Participants will:
* Receive standard chemotherapy to treat their cancer. * Provide samples of their blood, tissue, and fluid for genetic testing. * Visit the clinic every 4 weeks for check-ups and tests. * Complete questionnaires every 12 weeks.
Age 18 years or older.
Histological or radiological diagnosis of resectable, borderline resectable, or locally advanced PDAC.
Medically fit and planned to undergo laparoscopic procedure as part of standard of care.
Able to give informed consent for the study-related procedures performed during laparoscopy.
Presence of distant or lymph node metastases. Individuals with metastatic PDAC are not eligible.
Currently receiving adjuvant (Resectable and Borderline Resectable Cohorts) or systemic (Locally Advanced Cohort) anti-cancer therapy (chemotherapy or any other anti-cancer agent) with one exception: pre-operative therapy is permitted.
Not fit for chemotherapy as judged by the investigator.
Presence of brain metastases.
British Columbia Cancer Agency
Lead sponsor
Terry Fox Research Institute
Collaborator
BC Cancer Foundation
Collaborator